SCIENTISTS WORKING ON DRUG USE FOR KILLING HEAD LICE AS TREATMENT FOR CORONAVIRUS

 

From a century-old blood plasma therapy to an anti-malarial drug called hydroxychloroquine, the scientific community is exploring new ways to leverage existing treatments in the fight against the novel coronavirus, Good Morning America (GMA) has reported.

The latest surprising lead for researchers is an antiparasitic drug called ivermectin, used to treat head lice.

Research into the drug’s viability in treating COVID-19 is still in its early stages – far too soon to call it a breakthrough. But with the emergence of two preliminary studies yielding promising results, experts are expressing cautious optimism.

“Finding a safe, affordable, readily available therapy like ivermectin if it proves effective with rigorous evaluation has the potential to save countless lives,” said Dr. Nirav Shah, an infectious disease expert with the NorthShore University HealthSystem.

The development of ivermectin as an anti-parasitic treatment dates back to the 1970s and 1980s, first as a veterinary treatment for nematodes in cattle and later as a way to combat river blindness in humans. More recently, ivermectin is known for its topical use in treating head lice. Its use in treating those and other parasites has earned ivermectin a spot on the World Health Organisation’s list of essential medicines.

But now, researchers are looking to the drug for broader use in killing off SARS-Cov-2, the virus that causes COVID-19 – and earlier this month, a team of scientists in Australia found just that in test tubes.

“We found that even a single dose could essentially remove all viral RNA by 48 hours and that even at 24 hours there was a really significant reduction in it,” said Dr. Kylie Wagstaff, the leader of the team from Melbourne’s Monash Biomedicine Discovery Institute, Australia.

The coronavirus is not a parasite, but experts suggest that the drug essentially treats it like one and blocks the viral RNA from invading healthy cells. Unable to enter the cell, the RNA is slowed from replicating, giving the patient’s immune system more time to fight it off.

The Monash study took place at the cellular level, or in vitro. The next step, authors note, is “to determine the correct human dosage – ensuring the doses shown to effectively treat the virus in vitro are safe for humans.”

But with limited options elsewhere, experts say those early in vitro results are compelling.

More in Home

(JUST IN): Defunct Sosoliso Airlines Chairman dies of coronavirus in London

COVID-19: FG urged to establish training institute to upgrade health…

COVID-19: Videos of discrimination against Nigerians in China half…

FG begins payment of N30,000 to N-Power beneficiaries today, says…

Buhari hails European Union’s N21 billion donation to fight…
“There are numerous examples of drugs with in vitro activity not proving effective in human studies,” said Shah. “That being said, given there are no proven therapies against COVID-19 to date and we are in the midst of a pandemic, drugs that show promise in early in vitro or observational studies such as ivermectin should be rigorously evaluated to understand safety and effectiveness.”

Culled from Nigeria Tribune

Comments (0)
Add Comment